JP2013513613A5 - - Google Patents

Download PDF

Info

Publication number
JP2013513613A5
JP2013513613A5 JP2012543295A JP2012543295A JP2013513613A5 JP 2013513613 A5 JP2013513613 A5 JP 2013513613A5 JP 2012543295 A JP2012543295 A JP 2012543295A JP 2012543295 A JP2012543295 A JP 2012543295A JP 2013513613 A5 JP2013513613 A5 JP 2013513613A5
Authority
JP
Japan
Prior art keywords
alkyl
independently selected
haloalkyl
halo
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012543295A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013513613A (ja
JP5967827B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/059778 external-priority patent/WO2011072174A1/en
Publication of JP2013513613A publication Critical patent/JP2013513613A/ja
Publication of JP2013513613A5 publication Critical patent/JP2013513613A5/ja
Application granted granted Critical
Publication of JP5967827B2 publication Critical patent/JP5967827B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012543295A 2009-12-09 2010-12-09 Ｉｄｈ変異体をもつことを特徴とする癌治療用の治療的活性化合物 Expired - Fee Related JP5967827B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28512209P 2009-12-09 2009-12-09
US61/285,122 2009-12-09
US31353210P 2010-03-12 2010-03-12
US61/313,532 2010-03-12
PCT/US2010/059778 WO2011072174A1 (en) 2009-12-09 2010-12-09 Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015113075A Division JP2015193633A (ja) 2009-12-09 2015-06-03 Ｉｄｈ変異体をもつことを特徴とする癌治療用の治療的活性化合物

Publications (3)

Publication Number Publication Date
JP2013513613A JP2013513613A (ja) 2013-04-22
JP2013513613A5 true JP2013513613A5 (enExample) 2014-01-30
JP5967827B2 JP5967827B2 (ja) 2016-08-10

Family

ID=43638711

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012543295A Expired - Fee Related JP5967827B2 (ja) 2009-12-09 2010-12-09 Ｉｄｈ変異体をもつことを特徴とする癌治療用の治療的活性化合物
JP2015113075A Withdrawn JP2015193633A (ja) 2009-12-09 2015-06-03 Ｉｄｈ変異体をもつことを特徴とする癌治療用の治療的活性化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015113075A Withdrawn JP2015193633A (ja) 2009-12-09 2015-06-03 Ｉｄｈ変異体をもつことを特徴とする癌治療用の治療的活性化合物

Country Status (5)

Country Link
US (2) US20130035329A1 (enExample)
EP (1) EP2509600B1 (enExample)
JP (2) JP5967827B2 (enExample)
ES (1) ES2642109T3 (enExample)
WO (1) WO2011072174A1 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102985557B (zh) 2009-03-13 2018-06-15 安吉奥斯医药品有限公司 用于细胞增殖相关病症的方法和组合物
JP5756457B2 (ja) 2009-04-06 2015-07-29 アジオス ファーマシューティカルズ， インコーポレイテッド ピルビン酸キナーゼｍ２調節剤、治療組成物および関連する使用方法
DK2448581T3 (en) 2009-06-29 2017-03-13 Agios Pharmaceuticals Inc Therapeutic compositions and methods for their applications
PE20120693A1 (es) 2009-06-29 2012-07-04 Agios Pharmaceuticals Inc Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
EP2525790B1 (en) 2009-10-21 2020-05-27 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
WO2011050210A1 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
US9221792B2 (en) 2010-12-17 2015-12-29 Agios Pharmaceuticals, Inc N-(4-(azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase M2 (PMK2) modulators
WO2012088314A1 (en) 2010-12-21 2012-06-28 Agios Pharmaceuticals, Inc. Bicyclic pkm2 activators
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
PT3406251T (pt) 2011-05-03 2024-01-24 Agios Pharmaceuticals Inc Ativadores da piruvato-cinase para utilização em terapia
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) * 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
MX342326B (es) 2011-09-27 2016-09-26 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
SMT201800334T1 (it) 2012-01-06 2018-09-13 Agios Pharmaceuticals Inc Composti terapeuticamente attivi e loro metodi di utilizzo
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
WO2014062511A1 (en) 2012-10-15 2014-04-24 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
CA2903979A1 (en) * 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
US20160113911A1 (en) 2013-06-06 2016-04-28 The General Hospital Corporation Methods and compositions for the treatment of cancer
WO2015003355A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN105593215B (zh) 2013-07-11 2019-01-15 安吉奥斯医药品有限公司 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
MX375030B (es) 2013-07-11 2025-03-06 Agios Pharmaceuticals Inc Compuestos de n,6-bis(aril o heteroaril)-1,3,5-triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento de cancer.
WO2015010297A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
LT3077395T (lt) 2013-12-05 2018-02-12 Pfizer Inc. Pirolo[2,3-d]pirimidinilo, pirolo[2,3-b]pirazinilo ir pirolo[2,3-d]piridinilo akrilamidai
CN105980365B (zh) 2014-02-11 2019-06-21 拜耳医药股份公司 作为mIDH1抑制剂的苯并咪唑-2-胺
PE20170143A1 (es) 2014-02-11 2017-03-19 Bayer Pharma AG Benzimidazol-2-aminas como inhibidores de midh1
PH12021551647A1 (en) 2014-03-14 2022-06-06 Agios Pharmaceuticals Inc Pharmaceutical compositions of therapeutically active compounds
ES2913282T3 (es) * 2014-05-09 2022-06-01 Shanghai Syncores Tech Inc Ltd Producto intermedio de vortioxetina y procedimiento de síntesis del mismo
CA2961807A1 (en) * 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
WO2016044781A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
WO2016044787A1 (en) * 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
HUE062424T2 (hu) * 2014-09-19 2023-11-28 Forma Therapeutics Inc Piridin-2(1H)-on kinolinon származékok mint mutáns izocitrát dehidrogenáz inhibitorok
ES2905564T3 (es) 2014-12-22 2022-04-11 Us Health Inhibidores mutantes de IDH1 útiles para tratar el cáncer
US9624175B2 (en) * 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
US10407419B2 (en) 2015-04-21 2019-09-10 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
MX384883B (es) 2015-06-11 2025-03-14 Agios Pharmaceuticals Inc Métodos para usar activadores de piruvato cinasa.
JP2018525413A (ja) * 2015-08-24 2018-09-06 ザ メソディスト ホスピタル ユーイングファミリー腫瘍を治療する組成物及び方法
MD3362066T2 (ro) 2015-10-15 2022-08-31 Les Laboratoires Servier Sas Terapie combinată pentru tratamentul tumorilor maligne
HUE067449T2 (hu) 2015-10-15 2024-10-28 Servier Lab Ivozidenib, citarabin és daunorubicin vagy idarubicin kombinációs terápa akut mielogén leukémia kezelésére
MX2018008169A (es) * 2015-12-30 2019-02-20 Agios Pharmaceuticals Inc Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante.
WO2017153952A1 (en) * 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
EP3444237B1 (en) 2016-03-22 2020-10-28 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Iridinesulfonamide compound and use method thereof
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
CA3060390A1 (en) * 2017-04-24 2018-11-01 Aurigene Discovery Technologies Limited Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
CN109897044A (zh) * 2017-12-07 2019-06-18 北京大学 抗神经病理性疼痛化合物及其制备方法
CA3091792A1 (en) 2018-02-20 2019-08-29 Agios Pharmaceuticals, Inc. Methods of use for trisubstituted benzotriazole derivatives
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
SMT202300073T1 (it) 2018-05-16 2023-05-12 Forma Therapeutics Inc Inibizione di idh-1 mutante
CN108822082B (zh) * 2018-06-06 2020-11-03 青岛科技大学 一种含氟吡啶哌嗪酰胺类化合物及其应用
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CN116768806B (zh) * 2022-03-11 2026-01-02 中国农业大学 取代的1,2,3-三唑类化合物及其制备方法和在防治植物病害中的用途
CN114685399A (zh) * 2022-04-26 2022-07-01 河北广祥制药有限公司 一种乌拉地尔中间体1-(2-甲氧基苯基)哌嗪及其盐的制备方法
CN116425653A (zh) * 2023-03-22 2023-07-14 烟台盛凯伦化学科技有限公司 一种n,n’-二(对乙氧基苯基)-1,4-苯二甲亚胺的制备方法
WO2024238709A2 (en) * 2023-05-18 2024-11-21 Concarlo Therapeutics, Inc. Small molecule inhibitors of p27
WO2026088050A1 (en) * 2024-10-23 2026-04-30 Fondazione Per L'istituto Oncologico Di Ricerca (Ior) Small molecule inhibitor of foxa1 and foxa2 for the treatment of foxa1/foxa2-dependent cancers or other diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735127B1 (fr) * 1995-06-09 1997-08-22 Pf Medicament Nouvelles piperazines heteroaromatiques utiles comme medicaments.
GB9602166D0 (en) * 1996-02-02 1996-04-03 Zeneca Ltd Aminoheterocyclic derivatives
WO2004073619A2 (en) * 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
WO2004074438A2 (en) * 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
EP1836188A1 (en) * 2004-12-30 2007-09-26 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
EA018503B1 (ru) * 2007-07-20 2013-08-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Замещенные производные индазола, активные как ингибиторы киназы
GB0722779D0 (en) 2007-11-20 2008-01-02 Sterix Ltd Compound
CN102985557B (zh) * 2009-03-13 2018-06-15 安吉奥斯医药品有限公司 用于细胞增殖相关病症的方法和组合物
PE20120693A1 (es) * 2009-06-29 2012-07-04 Agios Pharmaceuticals Inc Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)

Similar Documents

Publication Publication Date Title
JP2018520195A5 (enExample)
JP2011006480A5 (enExample)
JP2020526561A5 (enExample)
TWI598098B (zh) 脂質異常症治療劑
JP2013531031A5 (enExample)
JP2013544860A5 (enExample)
JP2010540525A5 (enExample)
JP2011505347A5 (enExample)
JP2007518822A5 (enExample)
JP2010526814A5 (enExample)
RU2015120216A (ru) Ингибиторы тирозинкиназы брутона
JP2013505969A5 (enExample)
JP2017528498A5 (enExample)
JP2006517939A5 (enExample)
JP2013507415A5 (enExample)
JP2011527334A5 (enExample)
JP2011504903A5 (enExample)
JP2010523669A5 (enExample)
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
JP2006524660A5 (enExample)
JP2014532730A5 (ja) オピオイド受容体の調節物質およびそれを含む薬学的組成物
EP2228064A3 (en) Pharmaceutical composition containing glycopyrrolate and a beta2 adrenoceptor agonist
JP2008535803A5 (enExample)
RU2009123525A (ru) ПРОИЗВОДНЫЕ 5-СУЛЬФАНИЛМЕТИЛ[1,2,4}ТРИАЗОЛ[1,5-а]ПИРИМИДИН-7-ОЛА В КАЧЕСТВЕ АНТАГОНИСТОВ CXCR2
JP2011521938A5 (enExample)